The US drug safety regulator on Friday warned physicians that drugs used in
treating epilepsy, migraine and other conditions carry an increased risk of
suicidal thoughts and
behavior.


Julia Brill and John Huguenard view a tissue sample they used to gain insight into a popular epilepsy drug.

Patients given
anti-epileptics had twice the risk of suicidal thoughts and behavior (0.43
percent) compared with patients given a placebo (0.22 percent), the Food and
Drug Administration (FDA) said in a statement on its
website.

The risk corresponds
to about two more patients per 1,000 in the drug treatment groups becoming
suicidal than in the placebo groups, the FDA
said.

"FDA will be working with
manufacturers of marketed anti-epileptic drugs to include this new information in
the labeling for these products," it
said.

The FDA fielded data
starting in 2005 from some 200 studies done with 11 anti-epileptics, some of
which have been on the market for
decades.

The analysis included
27,863 patients in drug treatment groups and 16,029 patients in placebo groups.
There were four suicides among patients in the drug treatment groups and none
among patients in placebo
groups.

There were 105 reports
of suicidal thoughts or behavior in the drug-treated patients and 35 reports in
placebo-treated patients.

Via Times of India